Safety and Effectiveness of Vedolizumab for the Treatment of Pediatric Patients with Very Early Onset Inflammatory Bowel Diseases.

Fabiszewska, Sylwia; Derda, Edyta; Szymanska, Edyta; Osiecki, Marcin; Kierkus, Jaroslaw

Fabiszewska, Sylwia; Derda, Edyta; Szymanska, Edyta; Osiecki, Marcin; Kierkus, Jaroslaw.

Afiliação

Fabiszewska S; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Derda E; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Szymanska E; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Osiecki M; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.
Kierkus J; Department of Gastroenterology, Hepatology, Feeding Disorders and Pediatrics, The Children's Memorial Health Institute, 04-730 Warsaw, Poland.

J Clin Med ; 10(13)2021 Jul 05.

Article em En | MEDLINE | ID: mdl-34279480

Palavras-chave

inflammatory bowel disease; infliximab; infusion reaction; premedication

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: J Clin Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Polônia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google